Kenya vs Mongolia: Average cost of drugs for extensively drug-resistant tuberculosis
Kenya
1,800 constant 2022 US$
in 2024
Mongolia
1,900 constant 2022 US$
in 2024
Kenya rank
29th
Mongolia rank
28th
Average cost of drugs for extensively drug-resistant tuberculosis over time
- Kenya
- Mongolia
How they compare
Mongolia currently reports 1,900 constant 2022 US$ against 1,800 constant 2022 US$ in Kenya, a difference of 100 constant 2022 US$.
That makes Mongolia's figure about 1.1 times Kenya's.
The two have swapped places 2 times across 8 shared years of data; in 2017 it was Mongolia ahead.
Kenya ranks 29th and Mongolia ranks 28th of 56 countries.
Across the 2 decades both report, Kenya averaged higher in 1 and Mongolia in 1.
Head to head by decade
| Decade | Kenya | Mongolia | Difference | Ahead |
|---|---|---|---|---|
| 2010s | 4,500 constant 2022 US$ | 14,667 constant 2022 US$ | 10,167 constant 2022 US$ | Mongolia |
| 2020s | 2,706 constant 2022 US$ | 2,120 constant 2022 US$ | 586.4 constant 2022 US$ | Kenya |
Averages of every year both report within each decade.
Frequently asked questions
- Which has higher average cost of drugs for extensively drug-resistant tuberculosis, Kenya or Mongolia?
- Mongolia, at 1,900 constant 2022 US$ against 1,800 constant 2022 US$ in Kenya as of 2024.
- What is the difference in average cost of drugs for extensively drug-resistant tuberculosis between Kenya and Mongolia?
- 100 constant 2022 US$, with Mongolia ahead.
- How many years of comparable data are there for Kenya and Mongolia?
- 8 years are reported by both, from 2017 to 2024.
- How do Kenya and Mongolia rank globally for average cost of drugs for extensively drug-resistant tuberculosis?
- Kenya ranks 29th and Mongolia ranks 28th of 56 countries.
- Where does this data come from?
- WHO (2025) – with minor processing by Our World in Data, published as Average cost of drugs for extensively drug-resistant tuberculosis. Statizoid refreshes it automatically from the source and publishes the full history for both places.
Individual pages
About this data
Average cost of drugs spent per patient starting extensively drug-resistant tuberculosis treatment, excluding buffer stock.